Biocept Announces the Award of Japanese Patent for Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations in Tissue, Blood and Cerebrospinal Fluid
This is the third issued patent for the Primer-Switch technology as
"The Primer-Switch detection and amplification platform has the potential to find rare mutations in PCR reactions, which is highly useful when there is a need to detect rare genetic events or when more precise PCR amplification reactions are desired or required,"
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, and the utility and effectiveness of our intellectual property protections, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
LHA Investor Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-announces-the-award-of-japanese-patent-for-primer-switch-mutation-detection-and-amplification-improvement-platform-used-to-detect-rare-cell-mutations-in-tissue-blood-and-cerebrospinal-fluid-301136389.html